Rezolute (RZLT) Stock Overview

A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. More details

RZLT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 84.6% below our estimate of its fair value

Earnings are forecast to grow 62.1% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

RZLT Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Rezolute, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rezolute
Historical stock prices
Current Share Price	US$3.34
52 Week High	US$11.46
52 Week Low	US$1.07
Beta	0.67
1 Month Change	-6.96%
3 Month Change	-13.02%
1 Year Change	-6.44%
3 Year Change	56.07%
5 Year Change	-46.47%
Change since IPO	-99.49%

Recent updates

Analysis Article • Feb 16

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analysis Article • Oct 14

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Feb 18

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Summary Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses. Despite a small market size and competition from diazoxide, RZLT's innovative approach and phase 3 data potential make it a compelling, albeit cautious, investment. Read the full article on Seeking Alpha

Analysis Article • Feb 03

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Rezolute ( NASDAQ:RZLT ) stock...

Analysis Article • May 22

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Feb 13

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Key Insights Rezolute's estimated fair value is US$0.87 based on 2 Stage Free Cash Flow to Equity Rezolute's US$1.14...

Analysis Article • Sep 21

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Rezolute fair value estimate is US$2.26 Rezolute is estimated...

Analysis Article • Jul 25

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysis Article • Jan 31

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Sep 15

Rezolute GAAP EPS of -$0.37

Rezolute press release (NASDAQ:RZLT): Q4 GAAP EPS of -$0.37. Cash and cash equivalents totaled $150.4 million as of June 30, 2022.

Analysis Article • May 06

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Jan 12

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

If you want to know who really controls Rezolute, Inc. ( NASDAQ:RZLT ), then you'll have to look at the makeup of its...

Shareholder Returns

	RZLT	US Biotechs	US Market
7D	4.0%	-1.6%	-0.9%
1Y	-6.4%	34.4%	24.4%

Return vs Industry: RZLT underperformed the US Biotechs industry which returned 40.3% over the past year.

Return vs Market: RZLT underperformed the US Market which returned 26.7% over the past year.

Price Volatility

Is RZLT's price volatile compared to industry and market?
RZLT volatility
RZLT Average Weekly Movement	11.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RZLT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RZLT's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2010	68	Nevan Elam	www.rezolutebio.com

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

Rezolute, Inc. Fundamentals Summary

How do Rezolute's earnings and revenue compare to its market cap?
RZLT fundamental statistics
Market cap	US$355.19m
Earnings (TTM)	-US$81.48m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.3x

P/E Ratio

Is RZLT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RZLT income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$81.49m
Earnings	-US$81.48m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.78
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did RZLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/15 09:26
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julian Harrison	BTIG
Edward Nash	Canaccord Genuity
Pete Stavropoulos	Cantor Fitzgerald & Co.

Rezolute (RZLT) Stock Overview

Rewards

Risk Analysis

Rezolute, Inc. Competitors

Greenwich LifeSciences

Palisade Bio

Abeona Therapeutics

Immuneering

Price History & Performance

Recent News & Updates

Price target increased by 9.8% to US$5.63

Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

Price target increased by 9.1% to US$4.50

Rezolute, Inc. Provides Insights from Its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from Its Expanded Access Program in Tumor Hyperinsulinism

Recent updates

Price target increased by 9.8% to US$5.63

Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

Price target increased by 9.1% to US$4.50

Rezolute, Inc. Provides Insights from Its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from Its Expanded Access Program in Tumor Hyperinsulinism

Chief Financial Officer recently bought US$80k worth of stock

Rezolute, Inc. Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Price target decreased by 74% to US$4.13

New major risk - Share price stability

Forecast to breakeven in 2028

New minor risk - Profitability

Price target increased by 7.1% to US$15.00

Price target increased by 12% to US$14.89

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Rezolute, Inc., Annual General Meeting, Nov 19, 2025

No longer forecast to breakeven

Rezolute, Inc. Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer, Effective August 18, 2025

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute, Inc. announced that it has received $4.209995 million in funding

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $89.993096 million.

Rezolute, Inc. Announces Positive Recommendation After Independent Interim Analysis of Phase 3 Sunrize Study of Ersodetug in Congenital Hyperinsulinism

Chief Financial Officer recently bought US$58k worth of stock

Rezolute Appoints Erik Harris to Its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute, Inc. Provides Update on Its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

New major risk - Shareholder dilution

Rezolute Receives Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Chief Financial Officer recently bought US$53k worth of stock

New minor risk - Share price stability

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability